<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02758132</url>
  </required_header>
  <id_info>
    <org_study_id>Rosser 2015-1</org_study_id>
    <nct_id>NCT02758132</nct_id>
  </id_info>
  <brief_title>Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases</brief_title>
  <official_title>Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases: Clinical Testing and Feasibility of a Serum-based Metabolomics Profile</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Hawaii</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Hawaii</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a correlative study to characterize serum metabolites associated with bone
      deposition, growth and turnover in patients with newly diagnosed metastatic CRPC who are not
      currently receiving bone targeting agents.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low accruals
  </why_stopped>
  <start_date type="Actual">March 1, 2016</start_date>
  <completion_date type="Actual">September 6, 2016</completion_date>
  <primary_completion_date type="Actual">September 6, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure Change in Serum-based Metabolites Associated With Bone Deposition, Growth and Turnover in Patients Who Have CRPC With Clinical Evidence of Metastatic Disease to the Bone, All Using Gas Chromatography-time-of-flight Mass Spectrometry (GC-TOFMS).</measure>
    <time_frame>Prior to Registration, Registration, Day 1 of cycle 4 and 13</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure Time (Months) to Skeletal Related Event (SRE) of Patients on Therapy</measure>
    <time_frame>Day 1 of each S.O.C cycle (28 days), and until confirmed radiographic disease progression AND initiation of other standard OR investigational agents for prostate cancer, up to 5 years post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure Time (Months) to Progression-free Survival of Patients on Therapy</measure>
    <time_frame>Day 1 of each S.O.C cycle (28 days), and until confirmed radiographic disease progression AND initiation of other standard OR investigational agents for prostate cancer, up to 5 years post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure Time (Months) to Duration of Response of Patients on Therapy.</measure>
    <time_frame>Day 1 of each S.O.C cycle (28 days), and until confirmed radiographic disease progression AND initiation of other standard OR investigational agents for prostate cancer, up to 5 years post treatment</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Measure Change in Technetium Bone Scintigraphy on Therapy Via Technetium Bone Scintigraphy or Sodium Fluoride (NaF) PET/CT Imaging</measure>
    <time_frame>Prior to Registration, Day 1 of cycle 4 and 13, Post-Treatment Follow-up (up to 5 years post treatment)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Measure Change in Treatment Response Via RECIST Criteria</measure>
    <time_frame>Day 1 of each S.O.C cycle (28 days), and until confirmed radiographic disease progression AND initiation of other standard OR investigational agents for prostate cancer, up to 5 years post treatment</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Evaluate the Effect of Therapy on Quality of Life (QoL) in Patients Via QoL Questionnaire.</measure>
    <time_frame>Prior to Registration, Registration, Day 1 of cycle 4 and 13</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Evaluate the Effect of Therapy on Narcotic Use in Patients on Therapy Via Case Report Forms.</measure>
    <time_frame>Prior to Registration, Registration, Day 1 of cycle 4 and 13</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Alliance A031201</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Denosumab plus enzalutamide, abiraterone and prednisone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Denosumab plus enzalutamide alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Denosumab</intervention_name>
    <description>One 120 mg subcutaneous injection every four weeks. Protocol therapy will consist of 28-day cycles until no clinical benefit, confirmed disease progression or unacceptable toxicity.</description>
    <arm_group_label>Alliance A031201</arm_group_label>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enzalutamide</intervention_name>
    <description>160 mg enzalutamide by mouth daily</description>
    <arm_group_label>Alliance A031201</arm_group_label>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abiraterone</intervention_name>
    <description>1000 mg abiraterone by mouth daily</description>
    <arm_group_label>Alliance A031201</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>5 mg prednisone by mouth twice daily</description>
    <arm_group_label>Alliance A031201</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologic proof of adenocarcinoma of the prostate with clinical evidence of
             metastatic disease to the bone.

          -  Castrate resistant progression of prostate carcinoma, as shown by:

               -  Serum testosterone level &lt;50 ng/dL or prior bilateral orchiectomy. Treatment to
                  maintain castrate levels of testosterone should continue, and

                    -  Either symptomatic progression, or, if patient is asymptomatic then a rising
                       serum PSA in two occasions at least 1 week apart, with minimum pre-treatment
                       serum PSA of 5 ng/dL.

          -  Patients with nodal disease are eligible.

          -  Bi-dimensionally measurable disease within the bone.

          -  Life expectancy of at least 12 weeks.

          -  ECOG Performance status &lt; 2

          -  Adequate:

               -  Bone marrow function; absolute neutrophil count &gt; 1,500 mm3, platelet count of &gt;
                  100,000 mm3 and hemoglobin &gt; 9.0 gm/dl.

               -  Hepatic function; SGOT/SGPT and conjugated bilirubin less than twice the upper
                  limit of normal.

               -  Renal function; serum creatinine ≤ 2 mg/dL (or, if creatinine &gt; 2 mg/dL, then a
                  creatinine clearance of at least 35 ml/min (measured or estimated by the Cockroft
                  formula:

        CLcr = [(140-age) x wt (kg)]/[72 x serum creatinine (mg/dL)].

          -  No evidence of coagulopathy as indicated by PT &lt; 1.5X upper limit of normal.

          -  Serum calcium (corrected) from 8 to11.5 mg/dL (2 to 2.9 mmol/L) - Patients must sign
             an informed consent indicating that they are aware of the investigational nature of
             the study.

        Exclusion Criteria:

          -  Patients with variant histologies (e.g., ductal or small cell carcinoma).

          -  Patients with visceral disease are ineligible.

          -  Patients who have had prior Sipuleucel-T, docetaxel, cabazitaxel, abiraterone or
             enzalutamide as a single agent, or in combination therapy.

          -  Concurrent cancer chemotherapy, radiotherapy or surgery.

          -  Concurrent serious infection.

          -  Life threatening illness (e.g., congestive heart failure, uncontrolled angina or
             myocardial infarction in the prior six months).

          -  Hypertension uncontrolled by medication.

          -  Patients who are known to require invasive dental procedures.

          -  No known or suspected brain metastases (NOTE: patients with treated epidural disease
             are allowed)

          -  Administration of any investigational drug within 28 days prior to receipt of
             denosumab.

          -  Age ≤ 18 years of age
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Hawaii Cancer Center</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>April 11, 2016</study_first_submitted>
  <study_first_submitted_qc>April 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2016</study_first_posted>
  <results_first_submitted>September 10, 2019</results_first_submitted>
  <results_first_submitted_qc>September 10, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 2, 2019</results_first_posted>
  <last_update_submitted>November 6, 2019</last_update_submitted>
  <last_update_submitted_qc>November 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Castrate-resistant prostate cancer with bone metastases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Denosumab</mesh_term>
    <mesh_term>Prednisone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Alliance A031201</title>
          <description>Denosumab plus enzalutamide, abiraterone and prednisone
Denosumab: One 120 mg subcutaneous injection every four weeks. Protocol therapy will consist of 28-day cycles until no clinical benefit, confirmed disease progression or unacceptable toxicity.
Enzalutamide: 160 mg enzalutamide by mouth daily
Abiraterone: 1000 mg abiraterone by mouth daily
Prednisone: 5 mg prednisone by mouth twice daily</description>
        </group>
        <group group_id="P2">
          <title>Standard of Care</title>
          <description>Denosumab plus enzalutamide alone
Denosumab: One 120 mg subcutaneous injection every four weeks. Protocol therapy will consist of 28-day cycles until no clinical benefit, confirmed disease progression or unacceptable toxicity.
Enzalutamide: 160 mg enzalutamide by mouth daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Patient expired before completing study</population>
      <group_list>
        <group group_id="B1">
          <title>Alliance A031201</title>
          <description>Denosumab plus enzalutamide, abiraterone and prednisone
Denosumab: One 120 mg subcutaneous injection every four weeks. Protocol therapy will consist of 28-day cycles until no clinical benefit, confirmed disease progression or unacceptable toxicity.
Enzalutamide: 160 mg enzalutamide by mouth daily
Abiraterone: 1000 mg abiraterone by mouth daily
Prednisone: 5 mg prednisone by mouth twice daily</description>
        </group>
        <group group_id="B2">
          <title>Standard of Care</title>
          <description>Denosumab plus enzalutamide alone
Denosumab: One 120 mg subcutaneous injection every four weeks. Protocol therapy will consist of 28-day cycles until no clinical benefit, confirmed disease progression or unacceptable toxicity.
Enzalutamide: 160 mg enzalutamide by mouth daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Measure Change in Serum-based Metabolites Associated With Bone Deposition, Growth and Turnover in Patients Who Have CRPC With Clinical Evidence of Metastatic Disease to the Bone, All Using Gas Chromatography-time-of-flight Mass Spectrometry (GC-TOFMS).</title>
        <time_frame>Prior to Registration, Registration, Day 1 of cycle 4 and 13</time_frame>
        <population>Patient expired before completing study</population>
        <group_list>
          <group group_id="O1">
            <title>Alliance A031201</title>
            <description>Denosumab plus enzalutamide, abiraterone and prednisone
Denosumab: One 120 mg subcutaneous injection every four weeks. Protocol therapy will consist of 28-day cycles until no clinical benefit, confirmed disease progression or unacceptable toxicity.
Enzalutamide: 160 mg enzalutamide by mouth daily
Abiraterone: 1000 mg abiraterone by mouth daily
Prednisone: 5 mg prednisone by mouth twice daily</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Denosumab plus enzalutamide alone
Denosumab: One 120 mg subcutaneous injection every four weeks. Protocol therapy will consist of 28-day cycles until no clinical benefit, confirmed disease progression or unacceptable toxicity.
Enzalutamide: 160 mg enzalutamide by mouth daily</description>
          </group>
        </group_list>
        <measure>
          <title>Measure Change in Serum-based Metabolites Associated With Bone Deposition, Growth and Turnover in Patients Who Have CRPC With Clinical Evidence of Metastatic Disease to the Bone, All Using Gas Chromatography-time-of-flight Mass Spectrometry (GC-TOFMS).</title>
          <population>Patient expired before completing study</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measure Time (Months) to Skeletal Related Event (SRE) of Patients on Therapy</title>
        <time_frame>Day 1 of each S.O.C cycle (28 days), and until confirmed radiographic disease progression AND initiation of other standard OR investigational agents for prostate cancer, up to 5 years post treatment</time_frame>
        <population>Patient expired before completing study</population>
        <group_list>
          <group group_id="O1">
            <title>Alliance A031201</title>
            <description>Denosumab plus enzalutamide, abiraterone and prednisone
Denosumab: One 120 mg subcutaneous injection every four weeks. Protocol therapy will consist of 28-day cycles until no clinical benefit, confirmed disease progression or unacceptable toxicity.
Enzalutamide: 160 mg enzalutamide by mouth daily
Abiraterone: 1000 mg abiraterone by mouth daily
Prednisone: 5 mg prednisone by mouth twice daily</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Denosumab plus enzalutamide alone
Denosumab: One 120 mg subcutaneous injection every four weeks. Protocol therapy will consist of 28-day cycles until no clinical benefit, confirmed disease progression or unacceptable toxicity.
Enzalutamide: 160 mg enzalutamide by mouth daily</description>
          </group>
        </group_list>
        <measure>
          <title>Measure Time (Months) to Skeletal Related Event (SRE) of Patients on Therapy</title>
          <population>Patient expired before completing study</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measure Time (Months) to Progression-free Survival of Patients on Therapy</title>
        <time_frame>Day 1 of each S.O.C cycle (28 days), and until confirmed radiographic disease progression AND initiation of other standard OR investigational agents for prostate cancer, up to 5 years post treatment</time_frame>
        <population>Patient expired before completing study</population>
        <group_list>
          <group group_id="O1">
            <title>Alliance A031201</title>
            <description>Denosumab plus enzalutamide, abiraterone and prednisone
Denosumab: One 120 mg subcutaneous injection every four weeks. Protocol therapy will consist of 28-day cycles until no clinical benefit, confirmed disease progression or unacceptable toxicity.
Enzalutamide: 160 mg enzalutamide by mouth daily
Abiraterone: 1000 mg abiraterone by mouth daily
Prednisone: 5 mg prednisone by mouth twice daily</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Denosumab plus enzalutamide alone
Denosumab: One 120 mg subcutaneous injection every four weeks. Protocol therapy will consist of 28-day cycles until no clinical benefit, confirmed disease progression or unacceptable toxicity.
Enzalutamide: 160 mg enzalutamide by mouth daily</description>
          </group>
        </group_list>
        <measure>
          <title>Measure Time (Months) to Progression-free Survival of Patients on Therapy</title>
          <population>Patient expired before completing study</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measure Time (Months) to Duration of Response of Patients on Therapy.</title>
        <time_frame>Day 1 of each S.O.C cycle (28 days), and until confirmed radiographic disease progression AND initiation of other standard OR investigational agents for prostate cancer, up to 5 years post treatment</time_frame>
        <population>Patient expired before completing study</population>
        <group_list>
          <group group_id="O1">
            <title>Alliance A031201</title>
            <description>Denosumab plus enzalutamide, abiraterone and prednisone
Denosumab: One 120 mg subcutaneous injection every four weeks. Protocol therapy will consist of 28-day cycles until no clinical benefit, confirmed disease progression or unacceptable toxicity.
Enzalutamide: 160 mg enzalutamide by mouth daily
Abiraterone: 1000 mg abiraterone by mouth daily
Prednisone: 5 mg prednisone by mouth twice daily</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Denosumab plus enzalutamide alone
Denosumab: One 120 mg subcutaneous injection every four weeks. Protocol therapy will consist of 28-day cycles until no clinical benefit, confirmed disease progression or unacceptable toxicity.
Enzalutamide: 160 mg enzalutamide by mouth daily</description>
          </group>
        </group_list>
        <measure>
          <title>Measure Time (Months) to Duration of Response of Patients on Therapy.</title>
          <population>Patient expired before completing study</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Measure Change in Technetium Bone Scintigraphy on Therapy Via Technetium Bone Scintigraphy or Sodium Fluoride (NaF) PET/CT Imaging</title>
        <time_frame>Prior to Registration, Day 1 of cycle 4 and 13, Post-Treatment Follow-up (up to 5 years post treatment)</time_frame>
        <population>one subject enrolled and they discontinued early from trial, no analysis conducted</population>
        <group_list>
          <group group_id="O1">
            <title>Alliance A031201</title>
            <description>Denosumab plus enzalutamide, abiraterone and prednisone
Denosumab: One 120 mg subcutaneous injection every four weeks. Protocol therapy will consist of 28-day cycles until no clinical benefit, confirmed disease progression or unacceptable toxicity.
Enzalutamide: 160 mg enzalutamide by mouth daily
Abiraterone: 1000 mg abiraterone by mouth daily
Prednisone: 5 mg prednisone by mouth twice daily</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Denosumab plus enzalutamide alone
Denosumab: One 120 mg subcutaneous injection every four weeks. Protocol therapy will consist of 28-day cycles until no clinical benefit, confirmed disease progression or unacceptable toxicity.
Enzalutamide: 160 mg enzalutamide by mouth daily</description>
          </group>
        </group_list>
        <measure>
          <title>Measure Change in Technetium Bone Scintigraphy on Therapy Via Technetium Bone Scintigraphy or Sodium Fluoride (NaF) PET/CT Imaging</title>
          <population>one subject enrolled and they discontinued early from trial, no analysis conducted</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Measure Change in Treatment Response Via RECIST Criteria</title>
        <time_frame>Day 1 of each S.O.C cycle (28 days), and until confirmed radiographic disease progression AND initiation of other standard OR investigational agents for prostate cancer, up to 5 years post treatment</time_frame>
        <population>one subject enrolled and they discontinued early from trial, no analysis conducted</population>
        <group_list>
          <group group_id="O1">
            <title>Alliance A031201</title>
            <description>Denosumab plus enzalutamide, abiraterone and prednisone
Denosumab: One 120 mg subcutaneous injection every four weeks. Protocol therapy will consist of 28-day cycles until no clinical benefit, confirmed disease progression or unacceptable toxicity.
Enzalutamide: 160 mg enzalutamide by mouth daily
Abiraterone: 1000 mg abiraterone by mouth daily
Prednisone: 5 mg prednisone by mouth twice daily</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Denosumab plus enzalutamide alone
Denosumab: One 120 mg subcutaneous injection every four weeks. Protocol therapy will consist of 28-day cycles until no clinical benefit, confirmed disease progression or unacceptable toxicity.
Enzalutamide: 160 mg enzalutamide by mouth daily</description>
          </group>
        </group_list>
        <measure>
          <title>Measure Change in Treatment Response Via RECIST Criteria</title>
          <population>one subject enrolled and they discontinued early from trial, no analysis conducted</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Evaluate the Effect of Therapy on Quality of Life (QoL) in Patients Via QoL Questionnaire.</title>
        <time_frame>Prior to Registration, Registration, Day 1 of cycle 4 and 13</time_frame>
        <population>one subject enrolled and they discontinued early from trial, no analysis conducted</population>
        <group_list>
          <group group_id="O1">
            <title>Alliance A031201</title>
            <description>Denosumab plus enzalutamide, abiraterone and prednisone
Denosumab: One 120 mg subcutaneous injection every four weeks. Protocol therapy will consist of 28-day cycles until no clinical benefit, confirmed disease progression or unacceptable toxicity.
Enzalutamide: 160 mg enzalutamide by mouth daily
Abiraterone: 1000 mg abiraterone by mouth daily
Prednisone: 5 mg prednisone by mouth twice daily</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Denosumab plus enzalutamide alone
Denosumab: One 120 mg subcutaneous injection every four weeks. Protocol therapy will consist of 28-day cycles until no clinical benefit, confirmed disease progression or unacceptable toxicity.
Enzalutamide: 160 mg enzalutamide by mouth daily</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluate the Effect of Therapy on Quality of Life (QoL) in Patients Via QoL Questionnaire.</title>
          <population>one subject enrolled and they discontinued early from trial, no analysis conducted</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Evaluate the Effect of Therapy on Narcotic Use in Patients on Therapy Via Case Report Forms.</title>
        <time_frame>Prior to Registration, Registration, Day 1 of cycle 4 and 13</time_frame>
        <population>one subject enrolled and they discontinued early from trial, no analysis conducted</population>
        <group_list>
          <group group_id="O1">
            <title>Alliance A031201</title>
            <description>Denosumab plus enzalutamide, abiraterone and prednisone
Denosumab: One 120 mg subcutaneous injection every four weeks. Protocol therapy will consist of 28-day cycles until no clinical benefit, confirmed disease progression or unacceptable toxicity.
Enzalutamide: 160 mg enzalutamide by mouth daily
Abiraterone: 1000 mg abiraterone by mouth daily
Prednisone: 5 mg prednisone by mouth twice daily</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Denosumab plus enzalutamide alone
Denosumab: One 120 mg subcutaneous injection every four weeks. Protocol therapy will consist of 28-day cycles until no clinical benefit, confirmed disease progression or unacceptable toxicity.
Enzalutamide: 160 mg enzalutamide by mouth daily</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluate the Effect of Therapy on Narcotic Use in Patients on Therapy Via Case Report Forms.</title>
          <population>one subject enrolled and they discontinued early from trial, no analysis conducted</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were captured over 6 months</time_frame>
      <desc>adverse event collection performed by standard collection practices, medical chart review, disclosure from subject</desc>
      <group_list>
        <group group_id="E1">
          <title>Alliance A031201</title>
          <description>Denosumab plus enzalutamide, abiraterone and prednisone
Denosumab: One 120 mg subcutaneous injection every four weeks. Protocol therapy will consist of 28-day cycles until no clinical benefit, confirmed disease progression or unacceptable toxicity.
Enzalutamide: 160 mg enzalutamide by mouth daily
Abiraterone: 1000 mg abiraterone by mouth daily
Prednisone: 5 mg prednisone by mouth twice daily</description>
        </group>
        <group group_id="E2">
          <title>Standard of Care</title>
          <description>Denosumab plus enzalutamide alone
Denosumab: One 120 mg subcutaneous injection every four weeks. Protocol therapy will consist of 28-day cycles until no clinical benefit, confirmed disease progression or unacceptable toxicity.
Enzalutamide: 160 mg enzalutamide by mouth daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE 4.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>intracranial hemorrhage</sub_title>
                <description>subject was admitted to the hospital on 9/3/2016. Subject had a significant history of CVA (stroke) with atrial fibrillation. Patient elected hospice and care expired on 9/8/2016. The event was a grade 5 and deemed unrelated to study treatment.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Trial was terminated early due to low accrual of one subject. Data analysis not conducted due to the one enrolled subject not receiving all the treatment.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Stacy Mercado</name_or_title>
      <organization>University of Hawaii Cancer Center</organization>
      <phone>8084404561</phone>
      <email>smercado@cc.hawaii.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

